Loading...
XSHE
000538
Market cap14bUSD
Jun 11, Last price  
56.99CNY
1D
0.69%
1Q
3.92%
Jan 2017
-25.16%
Name

Yunnan Baiyao Group Co Ltd

Chart & Performance

D1W1MN
P/E
21.23
P/S
2.52
EPS
2.68
Div Yield, %
3.64%
Shrs. gr., 5y
—
Rev. gr., 5y
6.18%
Revenues
40.03b
+2.36%
2,448,395,0213,200,335,5134,115,716,8995,723,198,6677,171,784,04310,075,437,83411,312,322,43213,686,824,52515,814,790,88018,814,366,37220,738,126,20522,410,654,40424,314,614,04426,708,213,48729,664,673,86832,742,766,76336,373,919,01636,488,372,64939,111,292,15640,033,300,814
Net income
4.75b
+16.02%
230,370,274276,395,341336,790,481465,420,155603,719,565926,168,5801,210,908,6661,582,515,8432,321,453,7872,506,076,5012,770,841,4012,919,876,8123,144,981,4293,306,564,3174,183,727,5535,516,072,1782,804,916,7153,001,125,8874,093,782,0744,749,415,499
CFO
4.30b
+22.68%
286,277,104292,162,70060,503,123806,896,878460,548,807432,083,8840794,948,911341,641,5861,586,864,1792,179,500,4012,984,757,6821,155,689,9482,629,807,2362,104,744,8253,828,906,6325,223,278,2823,209,410,0323,502,742,3394,297,003,142
Dividend
May 10, 20242.077 CNY/sh
Earnings
Aug 25, 2025

Profile

Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, Chinese medicine resources, and tea. The company offers its products under the Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong brand names. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
URL
http://www.yunnanbaiyao.com.cn
IPO date
Dec 15, 1993
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
40,033,301
2.36%
39,111,292
7.19%
36,488,373
0.31%
Cost of revenue
29,456,181
32,365,493
31,642,188
Unusual Expense (Income)
NOPBT
10,577,120
6,745,799
4,846,185
NOPBT Margin
26.42%
17.25%
13.28%
Operating Taxes
917,647
695,451
536,593
Tax Rate
8.68%
10.31%
11.07%
NOPAT
9,659,473
6,050,349
4,309,592
Net income
4,749,415
16.02%
4,093,782
36.41%
3,001,126
7.00%
Dividends
(2,747,626)
Dividend yield
3.13%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
423,380
1,747,304
1,944,739
Long-term debt
383,414
346,795
573,667
Deferred revenue
295,494
238,811
178,622
Other long-term liabilities
607,487
653,123
671,003
Net debt
(23,101,899)
(26,912,618)
(22,308,989)
Cash flow
Cash from operating activities
4,297,003
3,502,742
3,209,410
CAPEX
(575,507)
Cash from investing activities
518,581
Cash from financing activities
(2,920,712)
FCF
9,309,234
5,544,859
6,892,488
Balance
Cash
13,435,097
17,029,532
15,471,836
Long term investments
10,473,596
11,977,185
9,355,559
Excess cash
21,907,028
27,051,152
23,002,976
Stockholders' equity
18,799,740
22,437,773
21,055,761
Invested Capital
21,585,463
20,281,273
20,044,197
ROIC
46.14%
30.01%
21.28%
ROCE
26.13%
15.76%
11.76%
EV
Common stock shares outstanding
1,785,495
1,787,678
1,579,540
Price
59.95
21.97%
49.15
-9.58%
54.36
-48.06%
Market cap
107,040,398
21.82%
87,864,362
2.33%
85,863,793
-54.45%
EV
83,972,637
60,977,982
63,578,128
EBITDA
10,888,616
7,118,996
5,299,794
EV/EBITDA
7.71
8.57
12.00
Interest
63,177
58,589
67,850
Interest/NOPBT
0.60%
0.87%
1.40%